强生据报洽购生物制药公司Therapeutics，两者正合作开发免疫疾药物

Core Viewpoint - Johnson & Johnson is in talks to acquire Protagonist Therapeutics, which could strengthen its product line amid competition from low-cost generics for its key immunotherapy drug Stelara [1] Group 1: Company Developments - Johnson & Johnson is currently collaborating with Protagonist Therapeutics on the development of immunology drugs [1] - Protagonist is also working with Takeda Pharmaceutical on a drug called Rusfertide, aimed at treating rare blood cancers [1] Group 2: Market Implications - The potential acquisition would help Johnson & Johnson consolidate its product offerings as it faces competition from generic versions of Stelara [1]